RELMADA 8-K Signals Executive Changes, Compensation Updates
Ticker: RLMD · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $414,500 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**RELMADA filed an 8-K about executive changes and pay, watch for details.**
AI Summary
RELMADA THERAPEUTICS, INC. filed an 8-K on January 11, 2024, reporting an event that occurred on January 5, 2024, related to the departure or election of directors/officers and their compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should monitor subsequent filings for details on who departed or was appointed and the specifics of any new compensation plans, as these changes can influence stock performance.
Why It Matters
Changes in executive leadership or compensation can significantly alter a company's future strategy and financial stability, directly affecting shareholder value.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty regarding future company performance and strategy.
Analyst Insight
Investors should await further details on the specific personnel changes and compensation arrangements mentioned in this 8-K to assess their potential impact on the company's future operations and financial outlook before making investment decisions.
Key Numbers
- $0.001 — par value per share (This is the stated par value for RELMADA's common stock.)
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — registrant filing the 8-K
- January 5, 2024 (date) — date of earliest event reported
- January 11, 2024 (date) — date of 8-K filing
- Nevada (company) — state of incorporation for RELMADA THERAPEUTICS, INC.
- 001-39082 (company) — Commission File Number for RELMADA THERAPEUTICS, INC.
- 45-5401931 (company) — IRS Employer Identification No. for RELMADA THERAPEUTICS, INC.
- 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 (company) — principal executive offices address for RELMADA THERAPEUTICS, INC.
- (786) 629-1376 (company) — telephone number for RELMADA THERAPEUTICS, INC.
- $0.001 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- RELMADA will disclose specific executive changes and compensation details in a subsequent filing or press release. (RELMADA THERAPEUTICS, INC.) — high confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 5, 2024.
What specific items are covered under Item 5.02 of this 8-K filing?
Item 5.02 covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
What is the par value of RELMADA THERAPEUTICS, INC.'s common stock?
The common stock of RELMADA THERAPEUTICS, INC. has a par value of $0.001 per share.
Where are the principal executive offices of RELMADA THERAPEUTICS, INC. located?
The principal executive offices of RELMADA THERAPEUTICS, INC. are located at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
What is the Commission File Number for RELMADA THERAPEUTICS, INC.?
The Commission File Number for RELMADA THERAPEUTICS, INC. is 001-39082.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-11 16:30:32
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
- $414,500 — y agreed to pay Dr. O'Gorman the sum of $414,500. If Dr. O'Gorman timely elects COBRA co
Filing Documents
- ea191520-8k_relmada.htm (8-K) — 27KB
- 0001213900-24-003000.txt ( ) — 196KB
- rlmd-20240105.xsd (EX-101.SCH) — 3KB
- rlmd-20240105_lab.xml (EX-101.LAB) — 33KB
- rlmd-20240105_pre.xml (EX-101.PRE) — 22KB
- ea191520-8k_relmada_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 11, 2024 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2